201 related articles for article (PubMed ID: 21613824)
1. Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFκB via suppression of GSK-3β expression.
Ban JO; Oh JH; Son SM; Won D; Song HS; Han SB; Moon DC; Kang KW; Song MJ; Hong JT
Cancer Biol Ther; 2011 Aug; 12(4):288-96. PubMed ID: 21613824
[TBL] [Abstract][Full Text] [Related]
2. Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone.
Ban JO; Kwak DH; Oh JH; Park EJ; Cho MC; Song HS; Song MJ; Han SB; Moon DC; Kang KW; Hong JT
Chem Biol Interact; 2010 Oct; 188(1):75-85. PubMed ID: 20540935
[TBL] [Abstract][Full Text] [Related]
3. Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3β, Snail1, and β-catenin in renal proximal tubule cells.
Lee YJ; Han HJ
Am J Physiol Renal Physiol; 2010 May; 298(5):F1263-75. PubMed ID: 20015942
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer.
Liao X; Zhang L; Thrasher JB; Du J; Li B
Mol Cancer Ther; 2003 Nov; 2(11):1215-22. PubMed ID: 14617795
[TBL] [Abstract][Full Text] [Related]
5. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism.
Akinyeke TO; Stewart LV
Cancer Biol Ther; 2011 Jun; 11(12):1046-58. PubMed ID: 21525782
[TBL] [Abstract][Full Text] [Related]
6. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation.
Ougolkov AV; Fernandez-Zapico ME; Bilim VN; Smyrk TC; Chari ST; Billadeau DD
Clin Cancer Res; 2006 Sep; 12(17):5074-81. PubMed ID: 16951223
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of lymphoma cell proliferation by peroxisomal proliferator-activated receptor-γ ligands via Wnt signaling pathway.
Liu JJ; Dai XJ; Xu Y; Liu PQ; Zhang Y; Liu XD; Fang ZG; Lin DJ; Xiao RZ; Huang RW; Huang HQ
Cell Biochem Biophys; 2012 Jan; 62(1):19-27. PubMed ID: 21837368
[TBL] [Abstract][Full Text] [Related]
8. New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9.
Lee CS; Kwon YW; Yang HM; Kim SH; Kim TY; Hur J; Park KW; Cho HJ; Kang HJ; Park YB; Kim HS
Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):472-9. PubMed ID: 19201691
[TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells.
Ougolkov AV; Fernandez-Zapico ME; Savoy DN; Urrutia RA; Billadeau DD
Cancer Res; 2005 Mar; 65(6):2076-81. PubMed ID: 15781615
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells.
Yoshino Y; Ishioka C
Sci Rep; 2015 Aug; 5():13249. PubMed ID: 26292722
[TBL] [Abstract][Full Text] [Related]
11. A screen for transcription factor targets of glycogen synthase kinase-3 highlights an inverse correlation of NFκB and androgen receptor signaling in prostate cancer.
Campa VM; Baltziskueta E; Bengoa-Vergniory N; Gorroño-Etxebarria I; Wesołowski R; Waxman J; Kypta RM
Oncotarget; 2014 Sep; 5(18):8173-87. PubMed ID: 25327559
[TBL] [Abstract][Full Text] [Related]
12. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer.
Schütz SV; Schrader AJ; Zengerling F; Genze F; Cronauer MV; Schrader M
PLoS One; 2011; 6(9):e25341. PubMed ID: 21980429
[TBL] [Abstract][Full Text] [Related]
14. Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes.
Liu J; Farmer SR
J Biol Chem; 2004 Oct; 279(43):45020-7. PubMed ID: 15308623
[TBL] [Abstract][Full Text] [Related]
15. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma.
Chaffer CL; Thomas DM; Thompson EW; Williams ED
BMC Cancer; 2006 Mar; 6():53. PubMed ID: 16519808
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
18. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
[TBL] [Abstract][Full Text] [Related]
19. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.
Kubota T; Koshizuka K; Williamson EA; Asou H; Said JW; Holden S; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3344-52. PubMed ID: 9699665
[TBL] [Abstract][Full Text] [Related]
20. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death.
Guan YF; Zhang YH; Breyer RM; Davis L; Breyer MD
Neoplasia; 1999 Oct; 1(4):330-9. PubMed ID: 10935488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
